# ImaCor, Inc.

> ImaCor, Inc. is a New York medical-device company that built the world's first and only hemodynamic transesophageal echocardiography (hTEE) platform for the intensive care unit. Its miniaturized, disposable ClariTEE probe can stay safely in a critically ill patient for up to 72 hours, giving clinicians a continuous, direct window onto the heart - preload, contractility, and right- and left-ventricular function - so they can guide fluids and drugs in real time instead of guessing. In 2022 ImaCor and Clarius Mobile Health launched the FDA-cleared Zura Handheld Hemodynamic Ultrasound, a pocket-sized, 22-ounce TEE system that puts that window in a clinician's hand.

- **Founded:** 2009
- **Headquarters:** Garden City, New York, United States
- **Founders:** Scott Roth, M.D. (Co-Founder & CEO), Steven Evans, M.D. (Co-Founder), Harold Hastings, Ph.D. (Co-Founder (Scientist))
- **Team size:** ~19 employees
- **Products:** ClariTEE Probe, Zura Imaging System, Zura Handheld Hemodynamic Ultrasound (with Clarius), hTEE 3-Step Method
- **Notable:** Developed the world's first and only hemodynamic transesophageal echocardiography (hTEE) platform, ClariTEE probe FDA-cleared to remain indwelling up to 72 hours, Launched the world's first handheld TEE system (Zura Handheld) with Clarius in 2022

## Products & services

- **ClariTEE Probe** — A miniaturized, disposable transesophageal echo probe FDA-cleared to remain indwelling for up to 72 hours, enabling episodic and continuous direct visualization of cardiac filling and function in the ICU.
- **Zura Imaging System** — ImaCor's mobile hTEE monitoring platform that pairs with the ClariTEE probe to display preload, contractility, and RV/LV size and function at the bedside.
- **Zura Handheld Hemodynamic Ultrasound (with Clarius)** — The world's first handheld transesophageal echocardiography system - a pocket-sized, 22-ounce device powered by Clarius Mobile Health, FDA-cleared in 2022.
- **hTEE 3-Step Method** — A structured, minimal-training protocol that lets multidisciplinary ICU teams acquire and interpret hemodynamic ultrasound views to guide fluid and drug decisions.

## Achievements

- Developed the world's first and only hemodynamic transesophageal echocardiography (hTEE) platform
- ClariTEE probe FDA-cleared to remain indwelling up to 72 hours
- Launched the world's first handheld TEE system (Zura Handheld) with Clarius in 2022
- Received CE Mark for the ClariTEE probe and Zura system
- Judge's Choice Award at the Octane Cardiovascular Tech Summit 2023
- Joined the American Heart Association Innovators' Network
- More than 15,000 patients managed with ImaCor hemodynamic ultrasound

## Latest updates

- **2023-01** — Won the Judge's Choice Award at the Octane Cardiovascular Tech Summit and joined the AHA Innovators' Network.
- **2022-06** — Launched the FDA-cleared Zura Handheld Hemodynamic Ultrasound with Clarius Mobile Health - the world's first handheld TEE system.
- **2022-06** — Announced an all-in-one hemodynamic management platform for the ICU.

## Links

- Website: https://imacorinc.com
- LinkedIn: http://www.linkedin.com/company/imacor-inc
- Twitter/X: https://twitter.com/ImaCor_hTEE
- Facebook: https://facebook.com/ImaCorMonitoring

---

Profile page: https://yespress.io/imacor-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-07